BUND FINANCE › Stocks › DGX
Quest Diagnostics Incorporated (DGX)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:01 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +7.21% above its 50-day average.
- It is +19.98% above its 200-day average (long-term uptrend).
- It sits at 96% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$10.8B | US$9.9B | US$9.3B | US$9.9B | US$11.0B |
| Net income | US$2.0B | US$946.0M | US$854.0M | US$871.0M | US$992.0M |
| EPS (diluted) | 15.53 | 7.98 | 7.52 | 7.69 | 8.75 |
| Gross margin | 39.0% | 34.7% | 33.2% | 32.9% | 31.9% |
| Operating margin | 22.1% | 14.5% | 13.6% | 13.6% | 14.5% |
| Net margin | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
| Free cash flow | US$1.8B | US$1.3B | US$864.0M | US$909.0M | US$1.4B |
| Total debt | US$4.8B | US$4.7B | US$5.5B | US$7.1B | US$6.9B |
| Cash | US$872.0M | US$315.0M | US$686.0M | US$549.0M | US$420.0M |
Compound annual growth: revenue 0.6% · net income -16.0% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 25.9x | 17.4x | 27.1x |
| EV / EBITDA | 14.8x | 11.2x | 16.5x |
| Operating margin | 14.6% | — | 3.6% |
| Net margin | 9.5% | — | -0.0% |
| Debt / equity | 1.20 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health pl…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice